Canine Atopic Eczema Drugs Is Fastest Growing Segment Fueling Growth Of Canine Atopic Dermatitis Treatment Drugs Market

Global Canine Atopic Dermatitis Treatment Drugs Market Size
Global Canine Atopic Dermatitis Treatment Drugs Market Size

 



The global Canine Atopic Dermatitis Treatment Drugs Market is estimated to be valued at US$ 1038.28 Mn in 2023 and is expected to exhibit a CAGR of 16% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

 
Canine atopic dermatitis is a chronic inflammatory skin disease caused by an allergic reaction in dogs. Treatment drugs aim to reduce inflammation, itching and skin lesions. Their growing adoption is helping pets and owners managing symptoms of the condition effectively.

Market key trends:
Rising pet ownership and growing awareness about animal health management are fueling demand for effective treatment options for canine atopic dermatitis. According to recent statistics, over 85% of U.S. households own a pet. This has led to significant R&D investments by key players to develop superior drugs delivering desired results. For instance, anti-pruritic and targeted therapies with minimal side effects are gaining popularity.

Segment Analysis
The global canine atopic dermatitis treatment drugs market is segmented on the basis of product type and distribution channel. By product type, the market is segmented into antihistamines, corticosteroids, immune-modulators, biologics, and others. The corticosteroids segment currently dominates the market due to its effectiveness in treating acute atopic dermatitis in dogs. However, the biologics segment is expected to witness fastest growth over the forecast period owing to its targeted mechanism of action with fewer side effects.

Key Takeaways
Global Canine Atopic Dermatitis Treatment Drugs Market Size is expected to witness high growth, exhibiting CAGR of 16% over the forecast period, due to increasing pet ownership and rising healthcare expenditure on pets.

Regional analysis
North America dominates the global market and is expected to maintain its dominance over the forecast period. This is attributed to growing pet adoption and high per capita animal healthcare expenditure in the region. Asia Pacific region is expected to witness fastest growth owing to improving veterinary infrastructure and increasing awareness about pet health in emerging countries such as China and India.

Key players
Key players operating in the canine atopic dermatitis treatment drugs market are Zeotis Inc, Elanco Animal Health Incorporated, Virbac, Kindred Biosciences, Inc., Nippon Zenyaku Kogyo Co., Ltd., Bioiberica S.A.U., Dechra Pharmaceuticals Plc, and Toray Industries, Inc. Zeotis Inc leads the market with its novel topical therapeutic product. Elanco Animal Health Incorporated has strong presence across markets due to its diversified product portfolio.

 

Get More Insights On This Topic: https://www.pressreleasebulletin.com/canine-atopic-dermatitis-treatment-drugs-market/

Post a Comment

Previous Post Next Post